Previous 10 | Next 10 |
The FDA's rejection on Thursday of a citizen petition related to Cassava Sciences' (NASDAQ:SAVA) experimental Alzheimer's treatment simufilam has rekindled a long-time debate over how the petitions are being used by some, especially rival companies and those with deep pockets. The abilit...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
The Citizens Petition filed against Cassava Sciences to the FDA was rejected. Cassava Sciences lead drug candidate Simufilam has the potential to be the best-selling drug of all time. Simufilam achieved the best AD drug trial cognition results to date this past summer. For f...
Cassava Sciences (NASDAQ:SAVA) closed up ~8% today, buoyed by the rejection of a citizen petition filed with the FDA that sought to pause a key trial of the company's Alzheimer's drug simufilam. In rejecting the petition, sent by attorney Jordan Thomas, formerly of Labaton Sucharow,...
AUSTIN, Texas, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and Drug Administration ("FDA") denied a Citizen Petition that was filed in August 2021 by...
The shares of Cassava Sciences (SAVA +16.0%) have surged after the FDA rejected a citizen petition filed by the lawyer, Jordan Thomas of Labaton Sucharow citing concerns over the quality of the studies into the company’s experimental Alzheimer’s drug simufilam. In a letter sent ...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Most treatments for Alzheimer's disease either lead to only temporary improvements in cognition or only minimally slow down the progression of the disease because they only inhibit peroxynitrite formation. Anavex 2-73 appears to almost stabilize Alzheimer's disease for long periods of...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Will you dare to wager on a stock that’s down, but is capable of moving higher? If so, then you’re invited to take a look at Texas-based clinical-stage biotechnology company Cassava Sciences (NASDAQ: ...
I investigate the reasoning behind Anvex Life Sciences' wild share price ride over the last year. The company’s lead compound Anavex 2-73 has a favorable safety profile, but what does the data show? I briefly touch on the companies Parkinson's disease therapy. For fur...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...